Researchers at Stanford have developed a method of culture media supplementation with inosine during the chimeric antigen receptor (CAR)-T cell manufacturing process which can alter and enhance CAR-T cell metabolism and anti-tumor functions.
Stanford Scientists have developed an innovative approach that enhances the antitumor efficacy of CAR T cells by overexpressing Adenosine Deaminase 1 (ADA), an enzyme responsible for metabolizing adenosine into inosine, to attenuate the immunosuppressive tumor microenvironment
Stanford researchers in the Wu Lab have developed hypoallergenic and immunogenic induced pluripotent stem cells that could be used as a cancer treatment or prophylactic.
This invention is an innovative breakthrough in cancer radiotherapy, offering a cutting-edge solution to address the challenges of radio-resistant and immunosuppressive tumors.
Mature pancreatic islets are the gold standard for transplantation-based approaches for islet replacement in type 1 and type 3c diabetes mellitus (T1D and T3cD), but this feature is offset by the scarcity of human cadaveric pancreas donors.
Immune checkpoint blockade, a class of immunotherapy treatment which works by blocking inhibitory receptors on T cells to improve immune responses, has proven to be a remarkable clinical advance in the treatment of many diseases, particularly in cancer.
Researchers at Stanford have created ligand-induced dimerization activating RNA editing (LIDAR), a versatile molecular sensor that turns the presence of a ligand into translation of an output protein.
Stanford researchers have developed an expanded catalog of compact transcription effector domains and fused them onto DNA binding domains to engineer synthetic transcription factors.
Stanford researchers have developed a method to activate, cryopreserve, and thaw T regulatory (Tregs) cells that preserves their viability, phenotype and function.
Researchers at Stanford University have developed a novel method for the first time to generate cardiac pericytes from human induced pluripotent stem cells that closely resemble primary cells.
One of the main shortcomings of the clinical use of Hematopoietic Stem Cells (HSCs) is the limited number of cells that can be safely harvested from a patient.
Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote immunosuppression, tumor growth, and metastasis. Consequently, these cells have received little attention as potential cancer immunotherapeutic agents.
Researchers at Stanford have developed a novel cell-free stem cell derived extracellular vesicle (EV) therapy powered by pulsed focused ultrasound (pFUS) that enhances its therapeutic and bioenergetic effect.